Myocardium-Targeted Micelle Nanomedicine That Salvages the Heart from Ischemia/Reperfusion Injury

Ren

2023

IJMS

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Although a cadre of therapeutic strategies have been made available for CVDs in the clinical setting, predominantly through medication and surgery, these do not fully address the clinical needs of patients with CVD. As a new technique for CVD treatment, nanocarriers are employed to modify and package medications to ease the targeting of tissues, cells and molecules within the cardiovascular system. Nanocarriers are made of biomaterials, metals, or a combination of these materials, with sizes similar to bioactive molecules such as proteins and DNA. Cardiovascular nanomedicine (CVN) has only surfaced in recent years and is still in its infancy. Ample studies have displayed promise for the clinical utility of nanomedicine techniques, courtesy of continued perfection in nanocarrier design to optimize drug delivery and treatment outcomes. Here in this review, we will summarize the research advances in the literature on nanoparticles in the management of CVDs, including ischemic and coronary heart disease (e.g., atherosclerosis, angina pectoris and myocardial infarction), myocardial ischemia-reperfusion injury, aortic aneurysm, myocarditis, hypertension, and pulmonary artery hypertension and thrombosis.

Section: Nanoparticles For the Treatment Of Cvdmentioning

confidence: 99%

Section: Nanoparticles For the Treatment Of Cvdmentioning

confidence: 99%

Nanoparticles in the New Era of Cardiovascular Therapeutics: Challenges and Opportunities

Ren

2023

IJMS

“…27 Silica cross-linked micelles (SCLMs) with ultrasmall sizes have long blood circulation half-lives due to the high-density PEG ligands and stealth property toward the reticuloendothelial system. 28 SCLMs have been successfully used as nanocarriers to deliver drugs to tumors, 29−31 heart, 32,33 and biofilms. 34 In the present study, three different sizes of SCLMs were prepared and their targeting ability to the injured kidney were investigated.…”

Section: ■ Introductionmentioning

confidence: 99%

Silica Cross-Linked Micelle-Based Theranostic System for the Imaging and Treatment of Acute and Chronic Kidney Injury

Wang

et al. 2023

ACS Appl. Bio Mater.

Self Cite

Acute kidney injury (AKI) is a common and serious disease with high mortality and morbidity, and the persistent inflammatory environment brought about by AKI promotes its deterioration into chronic kidney disease (CKD). An efficient and timely targeted drug delivery to the renal tubules is crucial for AKI treatment. Here, we prepared silica cross-linked micelles (SCLMs) with different sizes and studied their targeting ability to the injured kidney. It is found that the SCLMs with a size of 13 nm could rapidly accumulate and remain in the damaged kidney. Immunofluorescence results confirmed that SCLMs are selectively located in the damaged tubular cells but cannot be found in healthy renal tissue. Therefore, fluorescent dye-labeled SCLMs were used for the imaging of the injured kidney, which could reflect the status of the kidney injury. Furthermore, atorvastatin, an antioxidative and anti-inflammatory drug, was loaded in SCLMs as the therapeutic agents for the treatment of ischemia/reperfusion-induced AKI and CKD. Renal function indexes, such as tubular necrosis, collagen deposition, and inflammation, were effectively improved after the treatment.

“…However, such invasive surgical interventions have several limitations associated with the risk of reperfusion injury and bleeding [4]. The short half-life and the lack of specificity of pharmacological therapies, such as thrombolytic agents, also represents a limitation of current clinical protocols [5]. Stem cell therapy has been widely studied and developed to manage tissue regeneration in order to cope with the metastasis after MI.…”

Section: Introductionmentioning

confidence: 99%

Nanoparticle-based Drug Delivery System for Post Myocardial Infarction Management

Liu¹,

Ramponi²,

Fan³

et al. 2022

IJDDP

Review Nanoparticle-based Drug Delivery System for Post Myocardial Infarction Management Minxuan Liu, Chiara Ramponi, Xiaoxue Fan, Xinzhuang Zhang, Liang Cao, Zhenzhong Wang, and Wei Xiao * State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Jiangsu Kanion Pharmaceutical Co., Ltd., Lianyungang, 222001, China. * Correspondence: xw_kanion@163.com Received: 15 October 2022 Accepted: 2 November 2022 Published: 21 December 2022 Abstract: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the world. Myocardial infraction (MI) as one of the most harmful forms of ischaemic heart disease requires rigorous and tempestive approaches which are not met by current clinical interventions. Nanotechnology has developed promising clinical applications for imaging, diagnostic, gene delivery and tissue engineering, which makes this technology a potential candidate for novel therapeutic delivery approach. This review highlights several recent research reports regarding advances in drug delivery using nanoparticle-based (NP) strategies, as well as future challenges and opportunities.